Business Context and Reporting Period
This Form 8-K was filed by Emerald Bioscience, Inc. (formerly Nemus Bioscience, Inc.) on March 29, 2019. The report details a third drawdown under a Multi Draw Credit Agreement with Emerald Health Sciences Inc. (EHS). The company intends to use the proceeds for general corporate and working capital purposes.
Key Financial Metrics
- Drawdown Amount: $2,000,000
- Total Principal Drawn: $6,000,000 (as of March 29, 2019)
- Total Credit Facility: Up to $20,000,000 (unsecured revolving)
- Interest Rate: 7% per annum
- Maturity Date: October 5, 2022
- Conversion Price: $0.40 per share (convertible into 5,000,000 shares)
- Warrant Issued: 2,500,000 shares at an exercise price of $0.50 per share
The filing text does not provide clear values for revenue, profit, cash flow, margins, or overall liquidity beyond the specific credit facility details.
Material Changes
The primary material change is the increase in debt obligations. The company executed a third drawdown of $2,000,000, bringing the total outstanding principal under the credit facility to $6,000,000. Additionally, the company issued new unregistered equity securities (warrants) and increased the potential dilution through the convertible debt feature.
Outlook, Risks, and Contingencies
- Use of Proceeds: General corporate and working capital purposes.
- Default Risk: Upon an Event of Default, EHS may declare the entire outstanding principal and accrued interest immediately due and payable.
- Dilution Risk: The loan is convertible into common stock at $0.40 per share, and a warrant for 2,500,000 shares was issued at $0.50 per share.
- Regulatory Status: The issuance of convertible securities and warrants was exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D.
Investor Verification Checklist
- Verify the company's current cash position and ability to service the 7% interest on the $6,000,000 debt.
- Review the full text of the Credit Agreement (Exhibit 10.1) for specific definitions of "Event of Default."
- Assess the potential dilution impact of the 5,000,000 convertible shares and 2,500,000 warrant shares relative to the current share count.
- Confirm the company's progress on its business operations to justify the use of proceeds for working capital.